Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jazz Pharma Plc (NQ: JAZZ )

146.49 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 13, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 146.49
Bid (Size) 141.45 (1)
Ask (Size) 160.00 (1)
Prev. Close 146.49
Today's Range 146.49 - 146.49
52wk Range 117.64 - 189.00
Shares Outstanding 62,311,104
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
What Does HC Wainwright Have To Say On Avadel's Narcolepsy Candidate's Potential Approval?
Avadel Pharmaceuticals PLC (NASDAQ: AVDL) reported 1Q results and provided updated color on the U.S. marketing application for FT218. 
Via Benzinga
Jazz Pharmaceuticals Completes U.S. Divestiture Of Sunosi To Axsome Therapeutics, What's Next?
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has completed the divestiture of Sunosi (solriamfetol) in the U.S. 
Via Benzinga

Performance

YTD
+11.57%
+11.57%
1 Month
-10.71%
-10.71%
3 Month
+2.94%
+2.94%
6 Month
+5.25%
+5.25%
1 Year
-17.14%
-17.14%

More News

Read More
What 6 Analyst Ratings Have To Say About Jazz Pharmaceuticals
Via Benzinga
Jazz Pharma, Sumitomo Pharma Ink Licensing Pact For Sleeping Disorder Candidate
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Via Benzinga
Werewolf Therapeutics Shares Jump On Cancer Product Pact With Jazz Pharma
Via Benzinga
Jazz Pharma Reports Q1 Epidiolex Sales Increased 6% To $157.9M YoY
Via Benzinga
Jazz Pharmaceuticals: Q1 Earnings Insights
Via Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Via Benzinga
EXCLUSIVE: Aurora Cannabis CEO 'Absolutely Confident' Company Will Be EBITDA-Positive By Year's End
Via Benzinga
Axsome Therapeutics Stock Rockets As Its First FDA Approval Looks Imminent
Via Investor's Business Daily
Avicanna's Cannabinoid Drugs To Reach Brazil Via Its First 'Big Pharma' Deal
Via Benzinga
Syros' CDK12 Inhibitor Shows Anti Tumor Activity In Preclinical Studies
Via Benzinga
Expert Ratings For Jazz Pharmaceuticals
Via Benzinga
10 Biggest Price Target Changes For Wednesday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022
Via Benzinga
Why Axsome Therapeutics Stock Is Trading Higher
Via Benzinga
Axsome Acquires Sleep Disorder Drug From Jazz Pharma, Expanding Its Neuroscience Portfolio
Via Benzinga
The Daily Biotech Pulse: MEI Pharma Wilts On Adverse Regulatory Development, Decision Day For Zogenix, AN2 Therapeutics IPO
Via Benzinga
Jazz Pharmaceuticals's Return On Capital Employed Insights
Via Benzinga
Court Dismisses Canopy's Cannabis Patent Infringement Lawsuit Against Jazz's GW Pharma
Via Benzinga
Expert Ratings For Jazz Pharmaceuticals
Via Benzinga
Jazz Pharmaceuticals Announces Full Year And 4Q 2021 Financial Results
Via Benzinga
Jazz Pharmaceuticals: Q4 Earnings Insights
Via Benzinga
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.